Intensive glucose lowering and cardiovascular outcomes [5]

New England Journal of Medicine

Volumn 364, Issue 23, 2011, Pages 2263-2264

  Winterstein, Almut G ^a   Heckbert, Susan R ^b   Schambelan, Morris ^c  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; GLICLAZIDE; HEMOGLOBIN A1C; INDAPAMIDE PLUS PERINDOPRIL; ANTIHYPERTENSIVE AGENT;

CARDIOVASCULAR RISK; DIABETES MELLITUS; DRUG EXPOSURE; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HUMAN; INTENSIVE CARE; LETTER; LONG TERM CARE; PRIORITY JOURNAL; CARDIOVASCULAR DISEASE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; BLOOD PRESSURE MEASUREMENT; SURVIVAL RATE; HYPERTENSION; METHODOLOGY;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; THIAZOLIDINEDIONES; ANTIHYPERTENSIVE AGENTS; HYPERTENSION; RESEARCH DESIGN;

EID: 79958235027     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1103669     Document Type: Letter

References (3)

1. The ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011;364:818-28.
2. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.
3. Woodcock J, Sharfstein JM, Hamburg M. Regulatory action on rosiglitazone by the U.S. Food and Drug Administration. N Engl J Med 2010;363:1489-91.